SAN DIEGO, Feb. 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), have until April 9, 2024 to seek appointment as lead plaintiff of the Amylyx class action lawsuit. Captioned Shih v. Amylyx Pharmaceuticals, Inc., No. 24-cv-00988 (S.D.N.Y.), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx's top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Amylyx class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-amylyx-pharmaceuticals-inc-class-action-lawsuit-amlx.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for amyotrophic lateral sclerosis ("ALS") and other neurodegenerative diseases. Amylyx's products include, among others, AMX0035 (commercially referred to as "RELYVRIO" in the United States) for the treatment of ALS in adults in the United States.
The Amylyx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to ...